Tevogen Bio Soars 50% as Tevogen AI Teams Up with Microsoft for Startups to Accelerate Drug Development
Tevogen Bio (Nasdaq: TVGN), a clinical-stage biotech company developing immunotherapy treatments, announced today that its artificial intelligence division, Tevogen AI, has joined Microsoft’s Startup program. This partnership provides Tevogen access to Microsoft’s cutting-edge AI tools, accelerating the development of proprietary algorithms aimed at reducing the cost and time of drug discovery and development.
Tevogen’s leadership expressed optimism about the partnership’s potential to drive innovation in biotech, particularly in creating more affordable therapies for large patient populations. By leveraging Microsoft’s AI technology, Tevogen aims to enhance its capabilities in both infectious disease and cancer therapeutics.
Mittul Mehta, CIO and Head of Tevogen AI, emphasized the significance of the partnership, saying, “Joining Microsoft for Startups underscores Microsoft’s confidence in Tevogen’s ability to innovate and deliver.”
On Monday, Tevogen provided a top-line revenue forecast for its specialty care pipeline, projecting nearly $1 billion in its launch year and between $18 billion and $22 billion over the first five years. This forecast adds to Tevogen’s oncology projections of $1 billion in the launch year and $10–$14 billion over the first five years.
About Tevogen Bio
Tevogen is focused on developing off-the-shelf, genetically unmodified T cell therapies to treat infectious diseases, cancers, and neurological disorders. The company owns key intellectual property and has reported positive safety data from its proof-of-concept clinical trial.
